

Date: 12/11/2021

Ref: 21-22 368

Freedom of Information request

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 20/10/2021. Please see responses to your requests below.

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?

Treatment	No. of patients
Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent	-
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	-
Abemaciclib + Fulvestrant	16
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	-
Atezolizumab +Nab-paclitaxel/Paclitaxel	4
Capecitabine as a single agent	22
Carboplatin or Cisplatin as a single agent	-
Eribulin as a single agent or in combination	8
Everolimus + Exemestane	-
Fluorouracil	10
Fulvestrant as a single agent	-
Goserelin	-
Lapatinib	-
Neratinib	-
Olaparib	-
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	32
Palbociclib + Fulvestrant	-
Pertuzumab + Trastuzumab + Docetaxel	12
Platinum (e.g. carboplatin or cisplatin) as a single agent	-
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	15
Ribociclib + Fulvestrant	-
Talazoparib	-
Tamoxifen	-
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	14
Transtuzumab as a single agent	30
Trastuzumab emtansine	7
Transtuzumab deruxtecan	-
Any other active systemic anti-cancer therapy	223

We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

There were zero early/locally advanced (stages I to IIIc) breast cancer patients who were treated with an Aromatase Inhibitor.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team